Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Status unconfirmed · Phase 2

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating patients who have progressive or recurrent glioblastoma multiforme.

Key facts

Study ID

NCT00006656

Run by

Direct Therapeutics

Starts

2000-06-01

Last updated by the study team

2013-11-06

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
• Stanford University Medical Center — Stanford, California, United States
• University of Colorado Cancer Center — Denver, Colorado, United States
• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Emory University Hospital - Atlanta — Atlanta, Georgia, United States
• Evanston Northwestern Health Care — Evanston, Illinois, United States
• John F. Kennedy Medical Center — Edison, New Jersey, United States
• Barrett Cancer Center — Cincinnati, Ohio, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• Massey Cancer Center — Richmond, Virginia, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.